carvedilol has been researched along with Disease Models, Animal in 114 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the antioxidant effects of carvedilol (CARV), here, we aimed to evaluate CARV's effects against depression induced by the chronic unpredictable stress (CUS) model." | 8.12 | Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress. ( Cysne Filho, FMS; de Almeida Cysne, JC; de Aquino, GA; de Sousa, CNS; Macêdo, DS; Medeiros, IDS; Vasconcelos, GS; Vasconcelos, SMM, 2022) |
| " This study investigated the therapeutic benefit of adding rosuvastatin to low-dose carvedilol in protection against myocardial infarction (MI)." | 8.02 | Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. ( Awad, AS; Baraka, SA; El-Demerdash, E; El-Naga, RN; Elsherbini, DA; Tolba, MF, 2021) |
| "Rosacea, a chronic inflammatory skin disorder etiologically associated with immune cells and the antibacterial peptide cathelicidin LL-37, can be effectively treated by oral carvedilol administration." | 8.02 | A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages. ( Hu, L; Jiang, P; Li, M; Liu, W; Liu, Y; Sheng, L; Tao, M; Wang, X; Xu, Y; Yang, Y; Zhang, J, 2021) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 7.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 7.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 7.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "3mg/kg) or carvedilol (10mg/kg) was administrated orally 1h before histamine injection into animals of a histamine-induced paw edema model and orally daily for 11days into animals of a formaldehyde-induced arthritis model." | 7.85 | Carvedilol can attenuate histamine-induced paw edema and formaldehyde-induced arthritis in rats without risk of gastric irritation. ( Kamel, MM; Labib, DA; Osman, AS, 2017) |
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 7.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 7.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA." | 7.80 | Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. ( Chen, PS; Choi, EK; Lin, SF; Oh, S; Shen, MJ, 2014) |
| "The study was designed to compare the effects of ivabradine and carvedilol in acute viral myocarditis." | 7.78 | Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Na-Dan, Z; Qin, L; Teng, Z; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)." | 7.77 | Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011) |
| "The results of our study showed that rats that had been administered oral carvedilol for several days were more resistant to CA induced by airway obstruction, and when CA did occur, were more likely to be resuscitated." | 7.76 | The effects of carvedilol administration on cardiopulmonary resuscitation in a rat model of cardiac arrest induced by airway obstruction. ( Kurita, A; Taniguchi, T; Yamamoto, K, 2010) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 7.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| " Carvedilol, a nonselective beta-blocker, is widely used to prevent ventricular arrhythmias after myocardial infarction (MI)." | 7.75 | Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. ( Chen, J; He, B; Hu, X; Jiang, H; Lu, Z; Wen, H; Zhao, D, 2009) |
| " In this study the effect of pretreatment of carvedilol on adrenaline-induced changes in the serum electrolytes (Mg2+, K+, Ca2+, Na+) was evaluated in rats." | 7.75 | Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat. ( Akhter, N; Nahar, N, 2009) |
| "Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion." | 7.74 | Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 7.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "The purpose of the present study was to study the influence of left ventricular myocardial infarction on gap junction protein connexin 40 in the atria, and to observe the intervention function of carvedilol as an adrenergic receptor blocker." | 7.74 | The influence of carvedilol on atrial connexin 40 after myocardial infarction. ( Bao, M; Cao, F; Huang, C; Jiang, H; Li, X; Tang, Y, 2008) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 7.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats." | 7.73 | [Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 7.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties." | 6.48 | The mechanism of carvedilol in experimental viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "Carvedilol is a β-blocker used as a multifunctional neurohormonal antagonist that has been shown to act not only as an anti-oxidant but also as an anti-inflammatory drug." | 5.39 | Carvedilol decrease IL-1β and TNF-α, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis. ( de Araújo Júnior, RF; de Araújo, AA; de Lucena, HF; de Medeiros, CA; de Souza, LB; do Socorro Costa Feitosa Alves, M; Freitas, Mde L; Souza, TO, 2013) |
| "Carvedilol has been used in a limited number of studies examining oxidative injury." | 5.39 | The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model. ( Atilgan, D; Erdemir, F; Firat, F; Koseoglu, RD; Parlaktas, BS; Saylan, O; Yasar, A, 2013) |
| "Carvedilol showed enantioselective non-linear pharmacokinetic properties in both groups." | 5.36 | Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. ( Bernabeu, E; Bertera, F; Bramuglia, GF; Buontempo, F; Chiappetta, D; Di Verniero, CA; Höcht, C; Mayer, MA; Taira, CA, 2010) |
| "Treatment with carvedilol significantly decreased plasma creatinine levels after IRI (up to 168 hr) compared to controls (P < 0." | 5.36 | Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. ( De Velasco, MA; Hayashi, T; Ishii, T; Nishioka, T; Nose, K; Saitou, Y; Uemura, H, 2010) |
| "Treatment with carvedilol 1) reduced the pro-inflammatory cytokines and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with the amelioration of the elevated left ventricular diastolic pressure." | 5.33 | Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. ( Cheng, X; Ge, H; Guo, H; Li, B; Liao, YH; Wang, M, 2006) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 5.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 5.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| "Carvedilol was administered through direct gastric gavage." | 5.33 | [Effect of carvedilol on ryanodine receptor in heart failure]. ( Li, R; Liu, XY; Qian, YR; Yi, QJ, 2005) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carvedilol-treated animals exhibited a 78% reduction in infarct size compared to vehicle controls, such that the percentage of the left ventricle infarcted was reduced significantly from 16." | 5.28 | Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. ( Barone, FC; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR, 1991) |
| "Based on the antioxidant effects of carvedilol (CARV), here, we aimed to evaluate CARV's effects against depression induced by the chronic unpredictable stress (CUS) model." | 4.12 | Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress. ( Cysne Filho, FMS; de Almeida Cysne, JC; de Aquino, GA; de Sousa, CNS; Macêdo, DS; Medeiros, IDS; Vasconcelos, GS; Vasconcelos, SMM, 2022) |
| "Rosacea, a chronic inflammatory skin disorder etiologically associated with immune cells and the antibacterial peptide cathelicidin LL-37, can be effectively treated by oral carvedilol administration." | 4.02 | A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages. ( Hu, L; Jiang, P; Li, M; Liu, W; Liu, Y; Sheng, L; Tao, M; Wang, X; Xu, Y; Yang, Y; Zhang, J, 2021) |
| " This study investigated the therapeutic benefit of adding rosuvastatin to low-dose carvedilol in protection against myocardial infarction (MI)." | 4.02 | Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. ( Awad, AS; Baraka, SA; El-Demerdash, E; El-Naga, RN; Elsherbini, DA; Tolba, MF, 2021) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 3.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 3.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 3.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "We tested the non-selective β-blockers, carvedilol and nadolol, in house dust mite (HDM) driven murine asthma models where drugs were administered both pre- and post-development of the asthma phenotype." | 3.85 | Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype. ( Bond, RA; Eikenburg, DC; Joshi, R; Kim, H; Knoll, BJ; Valdez, D, 2017) |
| "3mg/kg) or carvedilol (10mg/kg) was administrated orally 1h before histamine injection into animals of a histamine-induced paw edema model and orally daily for 11days into animals of a formaldehyde-induced arthritis model." | 3.85 | Carvedilol can attenuate histamine-induced paw edema and formaldehyde-induced arthritis in rats without risk of gastric irritation. ( Kamel, MM; Labib, DA; Osman, AS, 2017) |
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 3.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 3.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA." | 3.80 | Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. ( Chen, PS; Choi, EK; Lin, SF; Oh, S; Shen, MJ, 2014) |
| "Beta-adrenoceptor blockers nebivolol and carvedilol do not affect diuresis and renal sodium excretion in intact rats, but significantly increase urinary excretion of sodium in animals with a model of heart failure caused by excessive physical exercise and injection of phenylephrine." | 3.78 | [Effect of the third generation beta-blockers on ion-regulating renal function in rats with heart failure model]. ( Buchneva, NV; Kuz'min, OB, 2012) |
| "The study was designed to compare the effects of ivabradine and carvedilol in acute viral myocarditis." | 3.78 | Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Na-Dan, Z; Qin, L; Teng, Z; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "The present study was performed to investigate whether or not carvedilol (a beta-adrenoreceptor antagonist) potentiates the anticonvulsive activity of gabapentin against ICES (Increasing current electroshock) and PTZ (Pentylenetetrazole) induced seizures in mice." | 3.77 | Influence of carvedilol on anticonvulsant effect of gabapentin. ( Goel, A; Goel, R; Kumar, Y, 2011) |
| "The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)." | 3.77 | Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011) |
| "To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in experimental pulmonary hypertension in rats." | 3.76 | Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. ( Abbate, A; Bogaard, HJ; Chang, PJ; Chau, VQ; Hoke, NN; Kasper, M; Kraskauskas, D; Mizuno, S; Natarajan, R; Salloum, FN; Voelkel, NF, 2010) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 3.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| "The results of our study showed that rats that had been administered oral carvedilol for several days were more resistant to CA induced by airway obstruction, and when CA did occur, were more likely to be resuscitated." | 3.76 | The effects of carvedilol administration on cardiopulmonary resuscitation in a rat model of cardiac arrest induced by airway obstruction. ( Kurita, A; Taniguchi, T; Yamamoto, K, 2010) |
| " Carvedilol, a nonselective beta-blocker, is widely used to prevent ventricular arrhythmias after myocardial infarction (MI)." | 3.75 | Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. ( Chen, J; He, B; Hu, X; Jiang, H; Lu, Z; Wen, H; Zhao, D, 2009) |
| " Furthermore, the application of patches containing SS extract-CTN mixture resulted in sustained release of carvedilol, which was able to control the hypertension in deoxycorticosterone acetate (DOCA) induced hypertensive rats through 24 hours." | 3.75 | Transdermal delivery of carvedilol in rats: probing the percutaneous permeation enhancement mechanism of soybean extract-chitosan mixture. ( Jain, S; Sapra, B; Tiwary, AK, 2009) |
| " In this study the effect of pretreatment of carvedilol on adrenaline-induced changes in the serum electrolytes (Mg2+, K+, Ca2+, Na+) was evaluated in rats." | 3.75 | Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat. ( Akhter, N; Nahar, N, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Histological studies have provided evidence that carvedilol can prevent cardiac hypertrophy in spontaneously hypertensive-stroke prone rats (SP) fed a high-fat and -salt diet." | 3.74 | Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. ( Barone, FC; Brooks, DP; Coatney, RW; Nelson, AH; Ohlstein, EH; Willette, RN, 2007) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 3.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 3.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion." | 3.74 | Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007) |
| "The purpose of the present study was to study the influence of left ventricular myocardial infarction on gap junction protein connexin 40 in the atria, and to observe the intervention function of carvedilol as an adrenergic receptor blocker." | 3.74 | The influence of carvedilol on atrial connexin 40 after myocardial infarction. ( Bao, M; Cao, F; Huang, C; Jiang, H; Li, X; Tang, Y, 2008) |
| "To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats." | 3.73 | [Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005) |
| "The study showed that L-NAME-induced hypertension has differential effects on endothelial connexins, which respond variously to carvedilol and atenolol." | 3.73 | Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. ( Ko, YS; Lee, PY; Su, CH; Tian, TY; Tsai, CH; Yeh, HI, 2006) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 3.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "Carvedilol (Coreg/Kredex) is an unselective vasodilating beta-blocker with potent antioxidant activity used in the treatment of hypertension, angina, and congestive heart failure." | 3.70 | Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. ( Barone, FC; Campbell, WG; Feuerstein, GZ; Nelson, AH, 1998) |
| "Carvedilol, a selective alpha(1) and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. ( Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL, 2000) |
| "The aim was to evaluate in a minipig model of acute myocardial infarction the cardioprotection provided by the beta adrenoceptor blocking and vasodilating activities present in carvedilol; comparison was made to the pure beta adrenoceptor antagonist, propranolol." | 3.68 | Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. ( Bril, A; DiMartino, MJ; Feuerstein, GZ; Linee, P; Poyser, RH; Ruffolo, RR; Slivjak, M; Smith, EF, 1992) |
| "Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties." | 2.48 | The mechanism of carvedilol in experimental viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "Carvedilol (CAR) is a third-generation β-adrenergic receptor antagonist with an α1-blocking effect." | 1.91 | Repurposing of carvedilol to alleviate bleomycin-induced lung fibrosis in rats: Repressing of TGF-β1/α-SMA/Smad2/3 and STAT3 gene expressions. ( Abbas, NAT; Abdelmageed, AF; Afifi, R; Hassan, HA; Mohammed, HO; Nafea, OE; Samy, W, 2023) |
| "Carvedilol is an adrenergic receptor antagonist." | 1.91 | Remyelinating activities of Carvedilol or alpha lipoic acid in the Cuprizone-Induced rat model of demyelination. ( Ahmed, KA; Ibrahim Fouad, G, 2023) |
| "Late carvedilol treatment did not lead to recovery of RV function." | 1.62 | [ ( Ahmadi, A; Beanlands, R; deKemp, RA; Mielniczuk, LM; Schock, S; Staines, WA; Stewart, DJ; Zelt, JGE, 2021) |
| "Carvedilol acts as a biased ligand to promote β1AR coupling to a Gi-PI3K-Akt-nitric oxide synthase 3 (NOS3) cascade and induces robust β1AR-cGMP-PKG signal." | 1.62 | Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility. ( Barbagallo, F; Deng, B; Liu, Y; Reddy, GR; Shi, Q; Wang, Q; Wang, Y; Wei, W; West, TM; Xiang, YK; Xu, B, 2021) |
| "Carvedilol was adiministered for 4 weeks starting at week 13." | 1.56 | Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling. ( Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2020) |
| "Treatment with carvedilol restored VMH lactate levels and improved the adrenaline (epinephrine) responses." | 1.51 | Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats. ( Chan, O; Farhat, R; Fisher, SJ; Knight, N; Sejling, AS; Su, G, 2019) |
| "Carvedilol (CVL) is an α-, β-blocker used to treat high blood pressure and congestive heart failure; however, some benefits beyond decreased blood pressure were observed clinically, suggesting the potential anti-inflammatory activity of CVL." | 1.48 | Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. ( Chen, A; Cheng, CC; Cheng, SM; Hua, KF; Li, LH; Lin, WY; Rao, YK; Wong, WT; Yang, SP, 2018) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| "Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks significantly counteracted the changes in hepatotoxicity markers and histopathological lesions induced by CCl4." | 1.46 | Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. ( Abdel-Sattar, SA; El-Bakly, WM; El-Demerdash, E; Mohamed, EA, 2017) |
| "Carvedilol was given at a dose of 2 mg/kg and nebivolol at a dose of 1 mg/kg by way of oral gavage." | 1.42 | The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats. ( Akgüllü, Ç; Boyacıoğlu, M; Eryılmaz, U; Güngör, H; Hekim, T; Karul, A; Meteoğlu, İ; Onbaşılı, OA, 2015) |
| "Pretreatment with carvedilol attenuated LPO elevation, mucus content and sulfhydryl group inhibitions." | 1.42 | Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis. ( Abuohashish, HM; Ahmed, MM; Al-Hosaini, KA; Al-Rejaie, SS; Fatani, AJ; Parmar, MY, 2015) |
| "Carvedilol has a statistically significant therapeutic effect, especially on functional recovery, and we found that carvedilol reduced secondary damage by inhibiting apoptosis and regulating the oxidant and antioxidant status." | 1.42 | Effect of Carvedilol on Secondary Damage in Experimental Spinal Cord Injury in Rats. ( Cengiz, SL; Esen, H; Karatas, Y; Savas, C; Toker, A, 2015) |
| "Recent findings from septic acute renal injury studies have implicated the mitochondrion as an important factor in kidney injury, and that increased sympathetic nerve activity may contribute to the induction of organ failure." | 1.42 | Low-dose carvedilol protects against acute septic renal injury in rats during the early and late phases. ( Abdel Kawy, HS, 2015) |
| "Carvedilol is a β-blocker used as a multifunctional neurohormonal antagonist that has been shown to act not only as an anti-oxidant but also as an anti-inflammatory drug." | 1.39 | Carvedilol decrease IL-1β and TNF-α, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis. ( de Araújo Júnior, RF; de Araújo, AA; de Lucena, HF; de Medeiros, CA; de Souza, LB; do Socorro Costa Feitosa Alves, M; Freitas, Mde L; Souza, TO, 2013) |
| "Carvedilol has been used in a limited number of studies examining oxidative injury." | 1.39 | The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model. ( Atilgan, D; Erdemir, F; Firat, F; Koseoglu, RD; Parlaktas, BS; Saylan, O; Yasar, A, 2013) |
| "Carvedilol treatment resulted in less left ventricular hypertrophy and dilatation." | 1.37 | Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2011) |
| "Carvedilol showed enantioselective non-linear pharmacokinetic properties in both groups." | 1.36 | Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. ( Bernabeu, E; Bertera, F; Bramuglia, GF; Buontempo, F; Chiappetta, D; Di Verniero, CA; Höcht, C; Mayer, MA; Taira, CA, 2010) |
| "Carvedilol treatment produced a significant increase in basal synaptic transmission and LTP in TgCRND8 mice, as compared to their vehicle-treated slices, in which basal neuronal transmission and LTP decreased." | 1.36 | Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. ( Arrieta-Cruz, I; Pasinetti, GM; Pavlides, C; Wang, J, 2010) |
| "Treatment with carvedilol significantly decreased plasma creatinine levels after IRI (up to 168 hr) compared to controls (P < 0." | 1.36 | Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. ( De Velasco, MA; Hayashi, T; Ishii, T; Nishioka, T; Nose, K; Saitou, Y; Uemura, H, 2010) |
| "Propranolol treatment also had no effects on these outcomes." | 1.35 | Blockade of adrenoreceptors inhibits the splenic response to stroke. ( Ajmo, CT; Collier, LA; Cuevas, J; Green, SM; Hall, AA; Leonardo, CC; Pennypacker, KR; Willing, AE; Womble, TA, 2009) |
| "Carvedilol treatment restored the IS reduction by postconditioning, possibly via other mechanism(s) of the ERK and Akt pathways." | 1.35 | Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. ( Maruyama, Y; Oikawa, M; Watanabe, K; Yaoita, H, 2008) |
| " Chronic administration of D-galactose for a period of 6 week results into a significant increase of acetylcholine esterase enzyme level." | 1.35 | Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice. ( Dogra, S; Kumar, A; Prakash, A, 2009) |
| "Treatment with carvedilol dramatically improved isometric tetanic force production at stimulus frequencies from 40 to 100 Hz (P < 0." | 1.34 | Myofibrillar protein oxidation and contractile dysfunction in hyperthyroid rat diaphragm. ( Matsunaga, S; Mishima, T; Sakamoto, M; Sugiyama, M; Wada, M; Yamada, T, 2007) |
| "Treatment with carvedilol 1) reduced the pro-inflammatory cytokines and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with the amelioration of the elevated left ventricular diastolic pressure." | 1.33 | Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. ( Cheng, X; Ge, H; Guo, H; Li, B; Liao, YH; Wang, M, 2006) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 1.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| "Carvedilol was administered through direct gastric gavage." | 1.33 | [Effect of carvedilol on ryanodine receptor in heart failure]. ( Li, R; Liu, XY; Qian, YR; Yi, QJ, 2005) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 1.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carvedilol at a lower dose (7." | 1.30 | Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. ( Donckier, J; Godfraind, T; Heyndrickx, GR; Kyselovic, J; Massart, PE; Wibo, M, 1999) |
| "Carvedilol-treated animals exhibited a 78% reduction in infarct size compared to vehicle controls, such that the percentage of the left ventricle infarcted was reduced significantly from 16." | 1.28 | Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. ( Barone, FC; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR, 1991) |
| "Postural hypotension is a common side effect observed in the treatment of hypertension with various drugs." | 1.27 | Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine. ( Bartsch, W; Böhm, E; Hooper, RG; Sponer, G; Strein, K, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.88) | 18.7374 |
| 1990's | 5 (4.39) | 18.2507 |
| 2000's | 38 (33.33) | 29.6817 |
| 2010's | 52 (45.61) | 24.3611 |
| 2020's | 18 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Asdaq, SMB | 1 |
| Alamri, AS | 1 |
| Alsanie, WF | 1 |
| Alhomrani, M | 1 |
| de Sousa, CNS | 1 |
| Medeiros, IDS | 1 |
| Vasconcelos, GS | 1 |
| de Aquino, GA | 1 |
| Cysne Filho, FMS | 1 |
| de Almeida Cysne, JC | 1 |
| Macêdo, DS | 1 |
| Vasconcelos, SMM | 1 |
| Ibrahim Fouad, G | 1 |
| Ahmed, KA | 1 |
| Abbas, NAT | 1 |
| Nafea, OE | 2 |
| Mohammed, HO | 1 |
| Samy, W | 1 |
| Abdelmageed, AF | 1 |
| Afifi, R | 1 |
| Hassan, HA | 1 |
| Adachi, M | 1 |
| Watanabe, M | 1 |
| Kurata, Y | 1 |
| Inoue, Y | 1 |
| Notsu, T | 1 |
| Yamamoto, K | 3 |
| Horie, H | 1 |
| Tanno, S | 1 |
| Morita, M | 1 |
| Miake, J | 1 |
| Hamada, T | 1 |
| Kuwabara, M | 1 |
| Nakasone, N | 1 |
| Ninomiya, H | 1 |
| Tsuneto, M | 1 |
| Shirayoshi, Y | 1 |
| Yoshida, A | 1 |
| Nishimura, M | 1 |
| Hisatome, I | 1 |
| Liu, B | 1 |
| Liu, YJ | 1 |
| Nguyen, LV | 1 |
| Ta, QV | 1 |
| Dang, TB | 1 |
| Nguyen, PH | 1 |
| Nguyen, T | 1 |
| Pham, TVH | 1 |
| Nguyen, TH | 1 |
| Baker, S | 1 |
| Le Tran, T | 1 |
| Yang, DJ | 1 |
| Kim, KW | 1 |
| Doan, KV | 1 |
| Ibrahim, WS | 1 |
| Ibrahim, IAAE | 1 |
| Mahmoud, MF | 1 |
| Mahmoud, AAA | 1 |
| Beiranvand, E | 1 |
| Ostad, SN | 1 |
| Ardakani, EM | 1 |
| Torkashvand, F | 1 |
| Sardari, S | 1 |
| Vaziri, B | 1 |
| Bussey, CT | 1 |
| Babakr, AA | 1 |
| Iremonger, RR | 1 |
| van Hout, I | 1 |
| Wilkins, GT | 1 |
| Lamberts, RR | 1 |
| Erickson, JR | 1 |
| Han, Y | 1 |
| Lai, J | 1 |
| Tao, J | 1 |
| Tai, Y | 1 |
| Zhou, W | 1 |
| Guo, P | 1 |
| Wang, Z | 1 |
| Wang, M | 2 |
| Wang, Q | 2 |
| Wang, Y | 3 |
| West, TM | 1 |
| Liu, Y | 3 |
| Reddy, GR | 1 |
| Barbagallo, F | 1 |
| Xu, B | 1 |
| Shi, Q | 1 |
| Deng, B | 1 |
| Wei, W | 1 |
| Xiang, YK | 1 |
| Ortiz, VD | 1 |
| Türck, P | 1 |
| Teixeira, R | 1 |
| Belló-Klein, A | 1 |
| de Castro, AL | 1 |
| Araujo, ASDR | 1 |
| Zhang, Y | 3 |
| Li, M | 2 |
| Li, L | 1 |
| Qian, G | 1 |
| Chen, Z | 1 |
| Liu, J | 1 |
| Fang, C | 1 |
| Huang, F | 1 |
| Guo, D | 1 |
| Zou, Q | 1 |
| Chu, Y | 1 |
| Yan, D | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 2 |
| Zhan, DY | 2 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Zelt, JGE | 1 |
| Schock, S | 1 |
| deKemp, RA | 1 |
| Stewart, DJ | 1 |
| Staines, WA | 1 |
| Ahmadi, A | 1 |
| Beanlands, R | 1 |
| Mielniczuk, LM | 1 |
| Baraka, SA | 1 |
| Tolba, MF | 1 |
| Elsherbini, DA | 1 |
| El-Naga, RN | 1 |
| Awad, AS | 1 |
| El-Demerdash, E | 2 |
| Sun, B | 1 |
| Yao, J | 1 |
| Chen, AW | 1 |
| Estillore, JP | 1 |
| Wang, R | 1 |
| Back, TG | 1 |
| Chen, SRW | 1 |
| Zhang, J | 1 |
| Jiang, P | 1 |
| Sheng, L | 1 |
| Tao, M | 1 |
| Hu, L | 1 |
| Wang, X | 1 |
| Yang, Y | 2 |
| Xu, Y | 1 |
| Liu, W | 2 |
| Mohamed, RMSM | 1 |
| Elshazly, SM | 1 |
| Abd El Motteleb, DM | 1 |
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 2 |
| Höcht, C | 2 |
| Osman, AS | 1 |
| Labib, DA | 1 |
| Kamel, MM | 1 |
| Joshi, R | 1 |
| Valdez, D | 1 |
| Kim, H | 1 |
| Eikenburg, DC | 1 |
| Knoll, BJ | 1 |
| Bond, RA | 2 |
| Skrzypiec-Spring, M | 1 |
| Haczkiewicz, K | 1 |
| Sapa, A | 1 |
| Piasecki, T | 1 |
| Kwiatkowska, J | 1 |
| Ceremuga, I | 1 |
| Wozniak, M | 1 |
| Biczysko, W | 1 |
| Kobierzycki, C | 1 |
| Dziegiel, P | 1 |
| Podhorska-Okolow, M | 1 |
| Szelag, A | 1 |
| Gomez, O | 1 |
| Okumura, K | 1 |
| Honjo, O | 1 |
| Sun, M | 1 |
| Ishii, R | 1 |
| Bijnens, B | 1 |
| Friedberg, MK | 1 |
| Akindele, AJ | 1 |
| Oludadepo, GO | 1 |
| Amagon, KI | 1 |
| Singh, D | 1 |
| Osiagwu, DD | 1 |
| Eibel, B | 1 |
| Kristochek, M | 1 |
| Peres, TR | 1 |
| Dias, LD | 1 |
| Dartora, DR | 1 |
| Casali, KR | 1 |
| Kalil, RAK | 1 |
| Lehnen, AM | 1 |
| Irigoyen, MC | 3 |
| Markoski, MM | 1 |
| Wong, WT | 1 |
| Li, LH | 1 |
| Rao, YK | 1 |
| Yang, SP | 1 |
| Cheng, SM | 1 |
| Lin, WY | 1 |
| Cheng, CC | 1 |
| Chen, A | 1 |
| Hua, KF | 1 |
| Park, SM | 1 |
| Hong, MK | 1 |
| Kim, SH | 1 |
| Jung, S | 1 |
| Kim, BK | 1 |
| Choi, D | 1 |
| Horta, AL | 1 |
| Figueiredo, VP | 1 |
| Leite, ALJ | 1 |
| Costa, GP | 1 |
| Menezes, APJ | 1 |
| Ramos, CO | 1 |
| Pedrosa, TCF | 1 |
| Bezerra, FS | 1 |
| Vieira, PMA | 1 |
| Talvani, A | 1 |
| Farhat, R | 1 |
| Su, G | 1 |
| Sejling, AS | 1 |
| Knight, N | 1 |
| Fisher, SJ | 1 |
| Chan, O | 1 |
| Yamamoto, H | 1 |
| Kawada, T | 1 |
| Shimizu, S | 1 |
| Hayama, Y | 1 |
| Shishido, T | 1 |
| Iwanaga, Y | 1 |
| Fukuda, K | 1 |
| Miyazaki, S | 1 |
| Sugimachi, M | 2 |
| Grandinetti, V | 1 |
| Carlos, FP | 1 |
| Antonio, EL | 1 |
| de Oliveira, HA | 1 |
| Dos Santos, LFN | 1 |
| Yoshizaki, A | 1 |
| Mansano, BSDM | 1 |
| Silva, FA | 1 |
| Porte, LA | 1 |
| Albuquerque-Pontes, GM | 1 |
| de Carvalho, PTC | 1 |
| Manchini, MT | 1 |
| Leal-Junior, EC | 1 |
| Tucci, PJF | 1 |
| Serra, AJ | 1 |
| Yamaura, S | 1 |
| Fukao, M | 1 |
| Ishida, K | 1 |
| Taguchi, M | 1 |
| Hashimoto, Y | 1 |
| de Araújo Júnior, RF | 1 |
| Souza, TO | 1 |
| de Medeiros, CA | 1 |
| de Souza, LB | 1 |
| Freitas, Mde L | 1 |
| de Lucena, HF | 1 |
| do Socorro Costa Feitosa Alves, M | 1 |
| de Araújo, AA | 2 |
| Saeidnia, S | 1 |
| Abdollahi, M | 1 |
| Choi, EK | 1 |
| Shen, MJ | 1 |
| Lin, SF | 1 |
| Chen, PS | 1 |
| Oh, S | 1 |
| Akgüllü, Ç | 1 |
| Hekim, T | 1 |
| Eryılmaz, U | 1 |
| Boyacıoğlu, M | 1 |
| Güngör, H | 1 |
| Meteoğlu, İ | 1 |
| Karul, A | 1 |
| Onbaşılı, OA | 1 |
| Abdel Kawy, HS | 1 |
| Fatani, AJ | 1 |
| Al-Hosaini, KA | 1 |
| Ahmed, MM | 1 |
| Abuohashish, HM | 1 |
| Parmar, MY | 1 |
| Al-Rejaie, SS | 1 |
| Knight, JM | 1 |
| Mak, G | 1 |
| Shaw, J | 1 |
| Porter, P | 1 |
| McDermott, C | 1 |
| Roberts, L | 1 |
| You, R | 1 |
| Yuan, X | 1 |
| Millien, VO | 1 |
| Qian, Y | 1 |
| Song, LZ | 1 |
| Frazier, V | 1 |
| Kim, C | 1 |
| Kim, JJ | 1 |
| Milner, JD | 1 |
| Mandal, PK | 1 |
| Luong, A | 1 |
| Kheradmand, F | 1 |
| McMurray, JS | 1 |
| Corry, DB | 1 |
| Karatas, Y | 1 |
| Cengiz, SL | 1 |
| Esen, H | 1 |
| Toker, A | 1 |
| Savas, C | 1 |
| Araújo Júnior, RF | 1 |
| Garcia, VB | 1 |
| Leitão, RF | 1 |
| Brito, GA | 1 |
| Miguel, Ede C | 1 |
| Guedes, PM | 1 |
| Bin-Dayel, AF | 1 |
| Abdel Baky, NA | 1 |
| Fadda, LM | 1 |
| Mohammad, RA | 1 |
| Al-Mohanna, F | 1 |
| Özsoy, AZ | 1 |
| Nursal, AF | 1 |
| Arıcı, A | 1 |
| Bütün, İ | 1 |
| Uysal, M | 1 |
| Irmak Sapmaz, H | 1 |
| Kunt İşgüder, Ç | 1 |
| Yılmaz Doğru, H | 1 |
| Taş, U | 1 |
| Zhang, R | 1 |
| Kang, X | 1 |
| Wang, F | 1 |
| Yu, P | 1 |
| Shen, J | 1 |
| Fu, L | 1 |
| Diogo, CV | 1 |
| Deus, CM | 1 |
| Lebiedzinska-Arciszewska, M | 1 |
| Wojtala, A | 1 |
| Wieckowski, MR | 1 |
| Oliveira, PJ | 1 |
| Nakamura, T | 1 |
| Fujita, T | 1 |
| Kishimura, M | 1 |
| Suita, K | 1 |
| Hidaka, Y | 1 |
| Cai, W | 1 |
| Umemura, M | 1 |
| Yokoyama, U | 1 |
| Uechi, M | 1 |
| Ishikawa, Y | 1 |
| Abdel-Sattar, SA | 1 |
| El-Bakly, WM | 1 |
| Mohamed, EA | 1 |
| Hanada, K | 1 |
| Asari, K | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Mita, M | 1 |
| Ogata, H | 1 |
| Crespo, MJ | 2 |
| Cruz, N | 2 |
| Altieri, PI | 1 |
| Escobales, N | 1 |
| Bartholomeu, JB | 1 |
| Vanzelli, AS | 3 |
| Rolim, NP | 1 |
| Ferreira, JC | 1 |
| Bechara, LR | 1 |
| Tanaka, LY | 1 |
| Rosa, KT | 2 |
| Alves, MM | 1 |
| Medeiros, A | 3 |
| Mattos, KC | 1 |
| Coelho, MA | 1 |
| Krieger, EM | 1 |
| Krieger, JE | 1 |
| Negrão, CE | 1 |
| Ramires, PR | 1 |
| Guatimosim, S | 1 |
| Brum, PC | 3 |
| Cao, F | 1 |
| Huang, C | 1 |
| Jiang, H | 2 |
| Li, X | 1 |
| Bao, M | 1 |
| Tang, Y | 1 |
| Zhao, JL | 1 |
| Yang, YJ | 1 |
| Pei, WD | 1 |
| Sun, YH | 1 |
| Zhai, M | 1 |
| Liu, YX | 1 |
| Gao, RL | 1 |
| Oikawa, M | 1 |
| Yaoita, H | 2 |
| Watanabe, K | 1 |
| Maruyama, Y | 2 |
| Jovanovic, D | 2 |
| Jovovic, D | 2 |
| Mihailovic-Stanojevic, N | 2 |
| Miloradovic, Z | 2 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 2 |
| Maksic, N | 2 |
| Djukanovic, L | 2 |
| Sun, T | 1 |
| Shen, LH | 1 |
| Chen, H | 1 |
| Li, HW | 1 |
| Guo, CY | 1 |
| Li, ZZ | 1 |
| Tang, CS | 1 |
| Sapra, B | 2 |
| Jain, S | 2 |
| Tiwary, AK | 2 |
| Ajmo, CT | 1 |
| Collier, LA | 1 |
| Leonardo, CC | 1 |
| Hall, AA | 1 |
| Green, SM | 1 |
| Womble, TA | 1 |
| Cuevas, J | 1 |
| Willing, AE | 1 |
| Pennypacker, KR | 1 |
| Morimoto, S | 1 |
| Wang, YY | 1 |
| Lu, QW | 1 |
| Tanaka, A | 1 |
| Ide, T | 1 |
| Miwa, Y | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| Wen, H | 1 |
| Lu, Z | 1 |
| He, B | 1 |
| Hu, X | 1 |
| Chen, J | 2 |
| Zhao, D | 1 |
| Aguilar-Torres, R | 1 |
| Kumar, A | 1 |
| Dogra, S | 1 |
| Prakash, A | 1 |
| Bogaard, HJ | 1 |
| Natarajan, R | 1 |
| Mizuno, S | 1 |
| Abbate, A | 1 |
| Chang, PJ | 1 |
| Chau, VQ | 1 |
| Hoke, NN | 1 |
| Kraskauskas, D | 1 |
| Kasper, M | 1 |
| Salloum, FN | 1 |
| Voelkel, NF | 1 |
| Arrieta-Cruz, I | 2 |
| Wang, J | 2 |
| Pavlides, C | 2 |
| Pasinetti, GM | 2 |
| Ono, K | 1 |
| Dickstein, DL | 1 |
| Zhao, W | 1 |
| Qian, X | 1 |
| Lamparello, A | 1 |
| Subnani, R | 1 |
| Ferruzzi, M | 1 |
| Ho, L | 1 |
| Hof, PR | 1 |
| Teplow, DB | 1 |
| Di Verniero, CA | 1 |
| Bertera, F | 1 |
| Buontempo, F | 1 |
| Bernabeu, E | 1 |
| Chiappetta, D | 1 |
| Mayer, MA | 1 |
| Bramuglia, GF | 1 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Sirvente, Rde A | 1 |
| Salemi, VM | 2 |
| Mady, C | 2 |
| Kurita, A | 1 |
| Taniguchi, T | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Takahama, H | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Fujita, M | 1 |
| Sasaki, H | 1 |
| Wakeno, M | 1 |
| Kim, J | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Minamino, T | 1 |
| Komamura, K | 1 |
| Kitakaze, M | 1 |
| Talan, MI | 1 |
| Ahmet, I | 1 |
| Xiao, RP | 1 |
| Lakatta, EG | 1 |
| Nahar, N | 1 |
| Akhter, N | 1 |
| Hayashi, T | 1 |
| De Velasco, MA | 1 |
| Saitou, Y | 1 |
| Nose, K | 1 |
| Nishioka, T | 1 |
| Ishii, T | 2 |
| Uemura, H | 1 |
| Zendaoui, A | 1 |
| Lachance, D | 1 |
| Roussel, E | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Yu, J | 1 |
| Zhao, J | 2 |
| Ge, Z | 1 |
| Du, Y | 1 |
| Goel, R | 1 |
| Goel, A | 1 |
| Kumar, Y | 1 |
| Yue-Chun, L | 3 |
| Li-Sha, G | 3 |
| Xue-Qiang, G | 2 |
| Jia-Feng, L | 3 |
| Teng, Z | 1 |
| Na-Dan, Z | 1 |
| Qin, L | 1 |
| Pimentel, Wde S | 1 |
| Ramires, FJ | 1 |
| Lanni, BM | 1 |
| Bilate, AM | 1 |
| Cunha-Neto, E | 1 |
| Oliveira, AM | 1 |
| Fernandes, F | 1 |
| Yasar, A | 1 |
| Erdemir, F | 1 |
| Parlaktas, BS | 1 |
| Atilgan, D | 1 |
| Koseoglu, RD | 1 |
| Saylan, O | 1 |
| Firat, F | 1 |
| Buchneva, NV | 1 |
| Kuz'min, OB | 1 |
| Padi, SS | 1 |
| Chopra, K | 1 |
| Singh, A | 2 |
| Naidu, PS | 1 |
| Gupta, S | 2 |
| Kulkarni, SK | 2 |
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 1 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 1 |
| Garg, V | 1 |
| Inoue, A | 1 |
| Yamashina, S | 1 |
| Yamazaki, J | 2 |
| Kim, W | 1 |
| Jeong, MH | 1 |
| Cha, KS | 1 |
| Hyun, DW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Hong, YJ | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, YK | 1 |
| Kim, MH | 1 |
| Cho, JG | 1 |
| Park, JT | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Strosznajder, RP | 1 |
| Jesko, H | 1 |
| Dziewulska, J | 1 |
| Liu, HB | 1 |
| Bian, SY | 1 |
| Yang, TS | 1 |
| Wang, L | 1 |
| Yi, J | 1 |
| Yang, X | 1 |
| Li, R | 1 |
| Yi, QJ | 1 |
| Qian, YR | 1 |
| Liu, XY | 1 |
| Li, B | 1 |
| Liao, YH | 1 |
| Cheng, X | 1 |
| Ge, H | 1 |
| Guo, H | 1 |
| Yeh, HI | 1 |
| Lee, PY | 1 |
| Su, CH | 1 |
| Tian, TY | 1 |
| Ko, YS | 1 |
| Tsai, CH | 1 |
| you, S | 1 |
| Cui, C | 1 |
| Gao, R | 1 |
| Nanjo, S | 1 |
| Yoshikawa, K | 1 |
| Togane, Y | 1 |
| Yamada, T | 1 |
| Mishima, T | 1 |
| Sakamoto, M | 1 |
| Sugiyama, M | 1 |
| Matsunaga, S | 1 |
| Wada, M | 1 |
| Arocho, L | 1 |
| Rosario, L | 1 |
| Barone, FC | 3 |
| Willette, RN | 1 |
| Nelson, AH | 2 |
| Ohlstein, EH | 2 |
| Brooks, DP | 1 |
| Coatney, RW | 1 |
| Yokoyama, A | 1 |
| Sato, N | 1 |
| Kawamura, Y | 1 |
| Hasebe, N | 1 |
| Kikuchi, K | 1 |
| Jiang-Hua, R | 1 |
| Peng-Lin, Y | 1 |
| Ji-Fei, T | 1 |
| Peng, C | 1 |
| Zhan-Qiu, Y | 1 |
| Campbell, WG | 1 |
| Feuerstein, GZ | 3 |
| Massart, PE | 1 |
| Donckier, J | 1 |
| Kyselovic, J | 1 |
| Godfraind, T | 1 |
| Heyndrickx, GR | 1 |
| Wibo, M | 1 |
| Gao, F | 1 |
| Lopez, BL | 1 |
| Christopher, TA | 1 |
| Gu, J | 1 |
| Lysko, P | 1 |
| Ruffolo, RR | 3 |
| Ma, XL | 1 |
| Yue, TL | 1 |
| Sakabe, A | 1 |
| Maehara, K | 1 |
| Smith, EF | 2 |
| Griswold, DE | 1 |
| Hillegass, LM | 1 |
| Slivjak, MJ | 1 |
| Davis, PA | 1 |
| DiMartino, MJ | 2 |
| Bril, A | 1 |
| Slivjak, M | 1 |
| Linee, P | 1 |
| Poyser, RH | 1 |
| Hamburger, SA | 1 |
| Bartsch, W | 1 |
| Sponer, G | 1 |
| Strein, K | 1 |
| Böhm, E | 1 |
| Hooper, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carvedilol and Disease Models, Animal
| Article | Year |
|---|---|
Toxicological and pharmacological concerns on oxidative stress and related diseases.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; B | 2013 |
β₂ AR agonists in treatment of chronic heart failure: long path to translation.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Carbazoles; Cardiomyopathy, Dilated; Carved | 2011 |
The mechanism of carvedilol in experimental viral myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Mice; Myocardi | 2012 |
111 other studies available for carvedilol and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Cardioprotective Potential of Garlic Oil and Its Active Constituent, Diallyl Disulphide, in Presence of Carvedilol during Chronic Isoprenaline Injection-Mediated Myocardial Necrosis in Rats.
Topics: Allyl Compounds; Animals; Antioxidants; Cardiotonic Agents; Carvedilol; Catalase; Disease Models, An | 2021 |
Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carvedilol; Depression; Disease M | 2022 |
Remyelinating activities of Carvedilol or alpha lipoic acid in the Cuprizone-Induced rat model of demyelination.
Topics: Animals; Carvedilol; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Mice; Mice, Inbred C | 2023 |
Repurposing of carvedilol to alleviate bleomycin-induced lung fibrosis in rats: Repressing of TGF-β1/α-SMA/Smad2/3 and STAT3 gene expressions.
Topics: Actins; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Agonists; Animals; Bleomycin; Carve | 2023 |
β-Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Cell Hypoxia; Cells, Cultured; Disease Models, Ani | 2019 |
Carvedilol Promotes Retinal Ganglion Cell Survival Following Optic Nerve Injury via ASK1-p38 MAPK Pathway.
Topics: Animals; Apoptosis; Carvedilol; Cell Survival; Disease Models, Animal; Mice, Inbred C57BL; Nerve Reg | 2019 |
Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice.
Topics: Adipose Tissue, White; Administration, Oral; Adrenergic Agents; Adrenergic beta-Antagonists; Animals | 2019 |
Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.
Topics: Animals; beta-Arrestin 2; Cardiomegaly; Carvedilol; Cytokines; Diet, High-Fat; Dietary Sugars; Disea | 2020 |
In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Cardiotoxicity; Carved | 2020 |
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Animals; Carvedilol; Coronary Artery Bypass; Diabetes | 2020 |
Sustaining Circulating Regulatory T Cell Subset Contributes to the Therapeutic Effect of Paroxetine on Mice With Diabetic Cardiomyopathy.
Topics: Animals; Carvedilol; Cell Differentiation; Cells, Cultured; Diabetic Cardiomyopathies; Diet, High-Fa | 2020 |
Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Cardiotonic Agents; Carvedilol; Cells, Cultured; C | 2021 |
Effects of Carvedilol and Thyroid Hormones Co-administration on Apoptotic and Survival Proteins in the Heart After Acute Myocardial Infarction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Apoptosis Regulatory Proteins; Carvedil | 2020 |
β-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.
Topics: Animals; beta-Arrestin 2; Carvedilol; Disease Models, Animal; Drug Repositioning; HEK293 Cells; Herp | 2020 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
[
Topics: Animals; Carvedilol; Disease Models, Animal; Echocardiography; Ephedrine; Male; Positron-Emission To | 2021 |
Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anticholesteremic Agents; Apoptosis; | 2021 |
Genetically and pharmacologically limiting RyR2 open time prevents neuronal hyperactivity of hippocampal CA1 neurons in brain slices of 5xFAD mice.
Topics: Alzheimer Disease; Animals; CA1 Region, Hippocampal; Carvedilol; Disease Models, Animal; Humans; Meg | 2021 |
A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antimicrobial Cationic Peptides; Carvedilol; Cathelicidins; Cytok | 2021 |
Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.
Topics: Animals; Apoptosis; Atenolol; beta-Arrestin 2; Blood Pressure; Cardio-Renal Syndrome; Cardiomegaly; | 2021 |
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Carvedilol can attenuate histamine-induced paw edema and formaldehyde-induced arthritis in rats without risk of gastric irritation.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Carbazoles; Carve | 2017 |
Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Carbazoles; Carvedilol; Disease Models, Animal; Inflam | 2017 |
Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carbazoles; Carvedilol; Di | 2018 |
Heart rate reduction improves biventricular function and interactions in experimental pulmonary hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Carvedilol; Disease Models, Animal; Dr | 2018 |
Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats.
Topics: Acute Kidney Injury; Animals; Antibiotics, Antineoplastic; Carbazoles; Carvedilol; Chemical and Drug | 2018 |
β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2018 |
Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome.
Topics: Adrenergic beta-Antagonists; Animals; Autophagy; Carvedilol; Cell Line; Cytokines; Disease Models, A | 2018 |
Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Aneurysm, Abd | 2019 |
The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Carvedilol; Catalase; Chagas Disease; Cytokines | 2018 |
Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Blood Glucose; Body Weight; Carvedilol; Catheteriza | 2019 |
Acute effects of intravenous carvedilol versus metoprolol on baroreflex-mediated sympathetic circulatory regulation in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Baroreflex | 2019 |
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.
Topics: Animals; Carvedilol; Catalase; Disease Models, Animal; Echocardiography; Female; Heart Failure; Hemo | 2019 |
Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.
Topics: Adrenergic beta-Antagonists; Animals; Biotransformation; Carbazoles; Carvedilol; Chronic Disease; Di | 2014 |
Carvedilol decrease IL-1β and TNF-α, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis.
Topics: Animals; Carbazoles; Carvedilol; Cyclooxygenase 2; Disease Models, Animal; Interleukin-1beta; Male; | 2013 |
Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs.
Topics: Administration, Oral; Adrenergic alpha-2 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Atri | 2014 |
The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Contrast Media; Diatrizoate; | 2015 |
Low-dose carvedilol protects against acute septic renal injury in rats during the early and late phases.
Topics: Acute Kidney Injury; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Glutathione; Inflammat | 2015 |
Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Carbazoles; Carvedilol; Colitis, Ulcera | 2015 |
Long-Acting Beta Agonists Enhance Allergic Airway Disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anti-Asthmatic Agents; Arrestins; Aspergill | 2015 |
Effect of Carvedilol on Secondary Damage in Experimental Spinal Cord Injury in Rats.
Topics: Animals; Apoptosis; Carbazoles; Carvedilol; Disease Models, Animal; In Situ Nick-End Labeling; Male; | 2015 |
Carvedilol Improves Inflammatory Response, Oxidative Stress and Fibrosis in the Alcohol-Induced Liver Injury in Rats by Regulating Kuppfer Cells and Hepatic Stellate Cells.
Topics: Animals; Biomarkers; Carbazoles; Carvedilol; Chemical and Drug Induced Liver Injury; Cytokines; Dise | 2016 |
Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model.
Topics: Amides; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carbazoles; Cardiomegaly; Carve | 2016 |
Effects of carvedilol on an ischemia/reperfusion model: Biochemical, histopathological and immunohistochemical evaluation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Carbazoles; | 2016 |
Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus, Experimental; Diabe | 2016 |
Carvedilol and antioxidant proteins in a type I diabetes animal model.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Glucose; Carbazoles; Carvedilol; Caspase 3 | 2017 |
Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy.
Topics: Animals; Antiviral Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Models, Animal; | 2016 |
Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Carbazoles; Carvedilol | 2017 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
The influence of carvedilol on atrial connexin 40 after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Carbazoles; Carvedilol; Connexins; Disease | 2008 |
Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Disease Models, Animal; Endothelin-1; Glyb | 2008 |
Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Disease Models, Ani | 2008 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Fibr | 2008 |
Effect of Asparagus racemosus extract on transdermal delivery of carvedilol: a mechanistic study.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Asparagus Plant; Blood Pressure; Carbaz | 2009 |
Blockade of adrenoreceptors inhibits the splenic response to stroke.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Carbazol | 2009 |
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dis | 2009 |
Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction.
Topics: Animals; Blotting, Western; Carbazoles; Carvedilol; Connexin 43; Disease Models, Animal; Fluorescent | 2009 |
Transdermal delivery of carvedilol in rats: probing the percutaneous permeation enhancement mechanism of soybean extract-chitosan mixture.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Chemistry, Phar | 2009 |
Found in translation: metoprolol improves survival more than carvedilol in a mouse model of inherited dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Model | 2009 |
Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice.
Topics: Acetylcholinesterase; Adrenergic beta-Antagonists; Aging; Animals; Behavior, Animal; Carbazoles; Car | 2009 |
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Topics: Adrenergic Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Hypertension, Pulmo | 2010 |
Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease.
Topics: Action Potentials; Adrenergic beta-Antagonists; Alzheimer Disease; Animals; Carbazoles; Carvedilol; | 2010 |
Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Carbazoles; Carvedilol; Disease Models, Animal; Female; Humans; M | 2011 |
Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Disease Models, Animal; Do | 2010 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
Association of physical training with beta-blockers in heart failure in mice.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin | 2010 |
The effects of carvedilol administration on cardiopulmonary resuscitation in a rat model of cardiac arrest induced by airway obstruction.
Topics: Administration, Oral; Adrenergic Antagonists; Airway Obstruction; Animals; Biomarkers; Blood Glucose | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Cardiac Pacing, Artificia | 2010 |
Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Drug Interacti | 2009 |
Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Apoptosis; Carbazoles; Carvedilol; Cr | 2010 |
Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Atrial Natri | 2011 |
Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.
Topics: Adrenergic Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood | 2011 |
Influence of carvedilol on anticonvulsant effect of gabapentin.
Topics: Amines; Analysis of Variance; Animals; Anticonvulsants; Brain; Carbazoles; Carvedilol; Convulsants; | 2011 |
Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Benzazepines; Carbazoles; Carvedilol; Coxsackieviru | 2012 |
The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Chagas Cardiomyopathy; Collagen; Crice | 2012 |
The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model.
Topics: Animals; Carbazoles; Carvedilol; Disease Models, Animal; Drug Administration Schedule; Kidney; Male; | 2013 |
[Effect of the third generation beta-blockers on ion-regulating renal function in rats with heart failure model].
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Carvedilol; Disease Models, Animal; D | 2012 |
Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Cyclosporine; Disease Mo | 2002 |
Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome.
Topics: Animals; Antioxidants; Brain; Carbazoles; Carvedilol; Catalase; Disease Models, Animal; Fatigue Synd | 2002 |
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
Role of antioxidants in chronic fatigue syndrome in mice.
Topics: Animals; Antioxidants; Brain; Carbazoles; Carvedilol; Catalase; Disease Models, Animal; Fatigue Synd | 2002 |
The effect of beta-blocker on hamster model BIO 53.58 with dilated cardiomyopathy determined using 123I-MIBG myocardial scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathy, Dilated; Ca | 2003 |
Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model.
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Coronary Restenosis; Disease Models, Animal; Probucol | 2005 |
Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Blood Pressure; Captopril; Carbazoles | 2005 |
Effect of carvedilol on neuronal survival and poly(ADP-ribose) polymerase activity in hippocampus after transient forebrain ischemia.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Cell Survival; D | 2005 |
[Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats].
Topics: Animals; Biphenyl Compounds; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Hemodynamics; | 2005 |
[Effect of carvedilol on ryanodine receptor in heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Calcium; Calcium Signaling; Calcium-Transpor | 2005 |
Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction.
Topics: Animals; Carbazoles; Carvedilol; Cytokines; Disease Models, Animal; Heart; Interleukin-10; Interleuk | 2006 |
Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Atenolol; Biomarkers; Blood Pressure; Blottin | 2006 |
Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Blotting, Western; Carbazoles; Carvedilo | 2007 |
Carvedilol prevents myocardial fibrosis in hamsters.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cricetinae; Disease Models, Animal; Ec | 2006 |
Myofibrillar protein oxidation and contractile dysfunction in hyperthyroid rat diaphragm.
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Diaphragm; Disease Models, Animal; Electric Stimulati | 2007 |
Chronic administration of carvedilol improves cardiac function in 6-month-old Syrian cardiomyopathic hamsters.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Cardiac Output; Cardiomyopathies; | 2007 |
Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Cardiomegaly; | 2007 |
Electrophysiological effects of carvedilol on rabbit heart pacemaker cells.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Atrioventricular Node; Calcium Channels, L- | 2007 |
Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Carbazo | 2008 |
Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Carbazoles; | 1998 |
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Topics: Actins; Animals; Antihypertensive Agents; Aortic Diseases; Blood Pressure; Carbazoles; Carotid Arter | 1999 |
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles | 2000 |
Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Carbazoles; Cardi | 2002 |
Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Dose-Response | 1992 |
Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 1992 |
Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Vessels; Dimethylformamide; D | 1991 |
Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine.
Topics: Animals; Blood Pressure; Carbazoles; Carvedilol; Disease Models, Animal; Guanethidine; Hypotension, | 1987 |